Sameera Rahman, MD
Family Medicine · Boardman, OHNPI 1205067378
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Olympus Corporation Of The Americas at 48.5% of the total. Reporting peaked in 2022 at $478 and has fallen 95.9% since, to $20 in 2025.
Across 22 payments — averaging $40.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$433
- Sanofi$110
- AbbVie$84
- Novo Nordisk$49
- Johnson & Johnson$38
- AstraZeneca$28
- plus $151 from 9 others
What the payments were for
- Consulting fees$43348%
- Speaking & faculty fees$11012%
- Food & beverage$35139%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 1 | $433 |
| Sanofi | 1 | $110 |
| AbbVie | 5 | $84 |
| Novo Nordisk | 3 | $49 |
| Johnson & Johnson | 1 | $38 |
| AstraZeneca | 2 | $28 |
| Exact Sciences | 1 | $22 |
| GSK | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Pfizer | 1 | $17 |
| Amgen | 1 | $16 |
| Viiv Healthcare Company | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Organon | 1 | $14 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iTIND System$433
- TOUJEO$110
How this compares
$894 in reported general payments places this provider in the 60th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 16 | $174 |
| Levothyroxine Sodium | 12 | $132 |
| Atorvastatin Calcium | 15 | $107 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $103 |
| Lisinopril | 13 | $79 |
| Azithromycin | 22 | $75 |
| Rosuvastatin Calcium | 18 | $70 |
| Losartan Potassium | 16 | $69 |
| Pravastatin Sodium | 12 | $62 |
| Metformin Hcl | 28 | $54 |
| Sertraline Hcl | 11 | $29 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Boardman
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.